Interim Management Statement - replacement

Mobeus Income & Growth 4 VCT PLC
16 November 2023
 

The following amendment has been made to the 'Interim Management Statement' announcement released on 15 November 2023 at 15:00 under RNS No 5916T.

 

The NAV per share has increased by 2.13 pence in the quarter.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

MOBEUS INCOME & GROWTH 4 VCT PLC

("the Company")

LEI:  213800IFNJ65R8AQW943

 

INTERIM MANAGEMENT STATEMENT

For the quarter ended 30 September 2023

 

Mobeus Income & Growth 4 VCT plc presents an Interim Management Statement for the quarter ended 30 September 2023. The statement also includes relevant financial information between the end of the period and the date of this statement.

 

NET ASSET VALUE AND TOTAL RETURN PER SHARE

                                            

At 30 September 2023

(unaudited)

At 30 June 2023

(unaudited)

Net assets attributable to shareholders

£86.59 million

£84.23 million

Shares in issue

110,556,762

110,556,762

 

Net asset value (NAV) per share

78.32 pence

76.19 pence

Cumulative dividends paid

158.20 pence

158.20 pence

Cumulative Total return (net asset value basis) per share since inception

236.52 pence

234.39 pence

The NAV per share has increased by 2.13 pence in the quarter (an increase of 2.8% from the NAV per share at 30 June 2023).

 

INVESTMENT ACTIVITY DURING THE PERIOD

 

New Investment during the period

On 26 July 2023, the Company completed a new investment of £0.40 million into Mable Therapy Limited, a digital health platform for speech therapy and counselling for children and young adults.

 

On 3 August 2023, the Company completed a new investment of £0.39 million into Branchspace Limited, a digital retailing consultancy and software provider to the aviation and travel industry.

 

Further Investments during the period

On 4 July 2023, a follow on equity investment of £0.33 million was made into Legatics Holdings Limited, a SaaS LegalTech software provider.

 

On 11 August 2023, a follow on loan investment of £0.13 million was made into Orri Limited, an intensive day care provider for adults with eating disorders.

 

INVESTMENT ACTIVITY AFTER THE PERIOD END

 

There has been no activity post-quarter.

 

SHARE BUYBACK AFTER THE PERIOD END

 

On 17 October 2023, the Company purchased 525,821 of its own ordinary shares at a price of 66.68 pence per share.

 

All shares bought back by the Company were subsequently cancelled.

 

DIVIDEND DECLARED AFTER THE PERIOD END

 

On 5 October 2023, a second interim dividend of 6.00 pence per share in respect of the year ending 31 December 2023 was declared and was paid on 8 November 2023 to all Shareholders whose names were on the register on 13 October 2023. Payment of this interim dividend has reduced NAV per share (shown above) to 72.32 pence and increased cumulative dividends paid to 164.20 pence per share.

 

DIVIDEND INVESTMENT SCHEME ("DIS")

 

 On 8 November 2023, 1,515,451 shares were allotted through the DIS during the period at a price of 70.19 pence per share.

 

Please note that all of the above information is unaudited.

 

Other than as described above, there were no material events during the period and to the date of this announcement.

 

For further information, please contact:

Gresham House Asset Management Limited,

Company Secretary: 020 7382 0999            

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings